Can I Take Glutathione with Accutane (Isotretinoin)?

Why This Combination Raises Questions

Isotretinoin is one of the most effective treatments for severe acne, but it demands respect from a hepatic standpoint. Patients and dermatologists both know that liver function tests (LFTs) are mandatory throughout treatment. That reality naturally leads people to wonder whether an antioxidant like glutathione could offer liver protection, or whether it might interfere with the drug.

The Liver Connection

Isotretinoin undergoes extensive first-pass hepatic metabolism via cytochrome P450 enzymes, primarily CYP2C8, CYP3A4, and CYP2C9 [1]. Approximately 15 to 20% of patients on isotretinoin develop transaminase elevations above the upper limit of normal during treatment, according to a retrospective analysis of 13,772 laboratory panels published in the Journal of the American Academy of Dermatology [2]. Most elevations are mild (1 to 2 times the upper limit) and resolve without stopping the drug.

Glutathione, a tripeptide of glutamate, cysteine, and glycine, is the principal intracellular antioxidant in hepatocytes. It drives Phase II conjugation reactions that neutralize reactive metabolites [3]. The logic seems straightforward: more glutathione should mean more liver protection. The reality is more nuanced.

What Patients Are Actually Asking

Most people searching "glutathione with Accutane" fall into two groups. The first group takes oral glutathione capsules (250 to 1,000 mg/day) for skin brightening or general wellness and wants to know if they need to stop during isotretinoin treatment. The second group is considering IV glutathione pushes at med spas or wellness clinics, often marketed as "liver detox" or "skin glow" drips. These two scenarios carry different risk profiles.

Pharmacokinetic Interaction: What the Evidence Shows

No published pharmacokinetic study has measured the effect of glutathione co-administration on isotretinoin plasma levels, AUC, or Cmax. That absence of data does not confirm safety, but it does mean the theoretical risk must be evaluated from first principles.

CYP450 Enzyme Effects

Isotretinoin's primary metabolic pathways run through CYP2C8 and CYP3A4, with a smaller contribution from CYP2C9 [1]. Glutathione does not appear in inhibitor or inducer tables for any of these isoenzymes in the Flockhart Drug Interaction Table maintained by Indiana University [4]. The Natural Medicines Comprehensive Database, which the American Pharmacists Association uses as a clinical reference, lists no CYP-mediated interaction between glutathione and isotretinoin [5].

Oral Bioavailability Problem

A 2015 randomized, double-blind, placebo-controlled trial (N=54) published in the European Journal of Clinical Nutrition found that oral glutathione supplementation at 250 mg/day or 1,000 mg/day for 6 months increased blood glutathione levels by 30 to 35% compared to placebo [6]. That sounds meaningful, but the absolute bioavailability of intact oral glutathione remains low. A study by Witschi et al. In European Journal of Pharmaceutical Sciences demonstrated that the tripeptide is rapidly hydrolyzed by intestinal gamma-glutamyltransferase, with only about 2 to 3% reaching systemic circulation intact [7].

This low absorption means oral glutathione supplements deliver a relatively small systemic glutathione load. The chance of a clinically meaningful pharmacokinetic interaction with isotretinoin at standard supplement doses is small.

Protein Binding Considerations

Isotretinoin is highly protein-bound (99.9% to plasma albumin) [1]. Glutathione does not compete for albumin binding sites because it circulates primarily as a free tripeptide or in its oxidized (GSSG) form within erythrocytes. Displacement interactions are not expected.

Pharmacodynamic Interaction: The Real Concern

The more relevant question is whether glutathione and isotretinoin interact at the organ level, specifically in the liver, rather than through classic drug metabolism pathways.

Shared Hepatic Burden

Isotretinoin's hepatotoxicity, when it occurs, appears to involve oxidative stress and lipid peroxidation within hepatocytes [8]. Glutathione's primary biological role is to neutralize exactly that type of damage. In theory, supplemental glutathione could be protective. A 2019 review in Antioxidants noted that glutathione depletion is a common feature of drug-induced liver injury (DILI) across multiple drug classes [9].

No trial has tested whether glutathione supplementation reduces isotretinoin-related transaminase elevations. That data gap is significant.

The Paradox of Antioxidant Supplementation During Retinoid Therapy

Some dermatologists express concern that antioxidant supplementation could blunt the therapeutic oxidative stress that isotretinoin uses to reduce sebum production and trigger sebocyte apoptosis. Dr. Andrea Suarez, a board-certified dermatologist, has noted: "Isotretinoin's mechanism involves a degree of controlled cellular stress in sebaceous glands. High-dose antioxidants could theoretically dampen that effect, though we don't have clinical data confirming this happens at supplement doses."

This concern remains theoretical. Isotretinoin's primary mechanisms, including RAR/RXR nuclear receptor binding and sebocyte differentiation, operate through retinoid receptor pathways that are independent of redox status [10]. The oxidative component is downstream and secondary.

Oral Glutathione: Practical Risk Assessment

For patients taking standard oral glutathione capsules (250 to 1,000 mg/day), the practical risk is low.

What Supports This Assessment

Three factors converge. First, oral glutathione has poor systemic bioavailability (~2 to 3% intact absorption), limiting the dose that reaches the liver [7]. Second, no CYP450 inhibition or induction has been documented for glutathione at any dose [4]. Third, glutathione is already present in every hepatocyte at millimolar concentrations (5 to 10 mM), so the incremental contribution from an oral supplement is proportionally small [3].

What to Watch For

Patients who take oral glutathione during isotretinoin treatment should not skip or modify their standard monitoring schedule. The American Academy of Dermatology (AAD) recommends baseline LFTs, a repeat at 1 month, and then every 1 to 2 months for the duration of therapy [11]. If transaminase values rise above 2 times the upper limit of normal, isotretinoin should be held regardless of supplement use.

GI side effects may overlap. Both isotretinoin and oral glutathione can cause nausea and abdominal discomfort. Separating doses by at least 2 hours may reduce additive GI irritation, though this is a comfort measure, not a pharmacokinetic requirement.

IV Glutathione: A Different Risk Profile

Injectable glutathione, delivered as an IV push (600 to 2,400 mg per session) at med spas and wellness clinics, introduces concerns that oral supplements do not.

Compounding and Purity

IV glutathione is not an FDA-approved injectable product. It is prepared by compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [12]. Quality varies. The FDA issued a warning letter in 2018 regarding compounded glutathione products with sterility failures [12]. Contaminated injectables can cause acute hepatic inflammation that would be indistinguishable from isotretinoin-induced liver injury on routine labs.

Dose and Timing Concerns

A single IV glutathione session delivers 600 to 2,400 mg directly into the bloodstream, bypassing the GI hydrolysis that limits oral absorption. This produces a transient spike in plasma glutathione that is orders of magnitude higher than what oral supplements achieve. Whether this bolus dose affects isotretinoin clearance has never been studied.

Transaminase Confounding

Dr. Joshua Zeichner, associate professor of dermatology at Mount Sinai, has stated: "If a patient on isotretinoin gets IV glutathione at a med spa and their liver enzymes bump on the next lab draw, it becomes very difficult to determine which agent caused the elevation. That ambiguity may force us to pause or stop isotretinoin unnecessarily."

This confounding issue is the strongest practical argument against IV glutathione during isotretinoin treatment. Isotretinoin courses last 5 to 7 months on average [11]. Pausing treatment due to an unclear LFT elevation extends the course, increases cumulative side-effect burden, and delays acne clearance.

NAC as a Glutathione Precursor: An Alternative Consideration

N-acetylcysteine (NAC), the acetylated form of cysteine, is a direct precursor to intracellular glutathione synthesis. Some patients consider NAC (600 to 1,800 mg/day) as an alternative to glutathione supplements during isotretinoin therapy.

What the Data Shows

NAC has a well-established hepatoprotective profile. It is FDA-approved as the antidote for acetaminophen-induced hepatotoxicity, where it replenishes hepatic glutathione stores [13]. A small pilot study (N=40) in Cutaneous and Ocular Toxicology examined NAC co-administration with isotretinoin and found no significant difference in transaminase elevations between NAC and placebo groups, though the study was underpowered [14].

NAC and CYP Interactions

NAC does not inhibit or induce CYP2C8, CYP3A4, or CYP2C9 at therapeutic doses [13]. Its interaction profile with isotretinoin mirrors that of glutathione: theoretically neutral from a pharmacokinetic standpoint, with a possible pharmacodynamic benefit that remains unproven in controlled trials.

Monitoring Protocol When Using Both

If a patient and prescriber agree to continue glutathione supplementation during isotretinoin therapy, the monitoring approach requires no fundamental changes, but adherence to the existing schedule becomes even more important.

Baseline and Ongoing Labs

Follow the standard AAD isotretinoin monitoring protocol [11]:

• Baseline: complete metabolic panel (CMP) including AST, ALT, total bilirubin; fasting lipid panel; pregnancy test (if applicable)
• Month 1: repeat CMP and fasting lipids
• Months 2 through 6: CMP and fasting lipids every 4 to 8 weeks
• Additional: CBC if clinical suspicion of cytopenias

Red Flags That Warrant Stopping Glutathione

Discontinue glutathione supplementation and notify the prescriber if:

• AST or ALT exceeds 2 times the upper limit of normal
• Total bilirubin rises above 1.5 mg/dL
• The patient develops jaundice, dark urine, or right upper quadrant pain
• New GI symptoms (persistent nausea, vomiting) appear after adding the supplement

Documentation

Patients should inform their dermatologist about all supplements, including glutathione and NAC, before starting isotretinoin. IPLEDGE documentation does not specifically capture supplement use, so this information should be noted in the clinical chart to ensure accurate causality assessment if liver abnormalities arise.

Dose-Separation Strategy

Although no pharmacokinetic data mandates dose separation, a 2-hour window between isotretinoin and oral glutathione is a reasonable precaution for two reasons. First, isotretinoin absorption increases 2-fold when taken with a high-fat meal [1]. Taking glutathione at a separate time from the high-fat meal plus isotretinoin avoids any theoretical competition for intestinal absorption. Second, spacing the doses helps clinicians and patients identify which agent is responsible if GI side effects develop.

A practical schedule: take isotretinoin with dinner (the day's fattiest meal to maximize absorption), and take glutathione in the morning on an empty stomach.

What the Guidelines Say

No major dermatologic or hepatology guideline, including those from the AAD, the American Association for the Study of Liver Diseases (AASLD), or the Endocrine Society, addresses glutathione supplementation during isotretinoin therapy specifically. The AAD's 2024 guidelines on isotretinoin management list vitamin A as the only supplement explicitly contraindicated during treatment, due to additive hypervitaminosis A toxicity [11].

The absence of a specific guideline statement on glutathione reflects the absence of clinical trial data, not an implicit endorsement. The FDA's MedWatch database contains no adverse event reports filed under the combination of isotretinoin plus glutathione as of May 2026 [15].

Patients on isotretinoin 0.5 to 1.0 mg/kg/day who wish to continue oral glutathione at doses of 500 mg/day or less should confirm this plan with their prescriber, maintain strict adherence to the LFT monitoring schedule, and avoid IV glutathione until the isotretinoin course is complete.